Xenetic Biosciences, Inc. (XBIO) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Xenetic Biosciences, Inc. (NASDAQ:XBIO) posted its quarterly earnings data on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03), Bloomberg Earnings reports.

Shares of Xenetic Biosciences (NASDAQ:XBIO) opened at $2.18 on Thursday. Xenetic Biosciences has a 1-year low of $1.75 and a 1-year high of $5.90.

Separately, Zacks Investment Research downgraded shares of Xenetic Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, September 28th.

ILLEGAL ACTIVITY NOTICE: “Xenetic Biosciences, Inc. (XBIO) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/16/xenetic-biosciences-inc-xbio-releases-quarterly-earnings-results-misses-expectations-by-0-03-eps.html.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply